AlloVir Balance Sheet Health
Financial Health criteria checks 6/6
AlloVir has a total shareholder equity of $120.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $131.0M and $10.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$129.61m |
| Equity | US$120.29m |
| Total liabilities | US$10.70m |
| Total assets | US$130.99m |
Recent financial health updates
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely
Jul 13
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully
Feb 09Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Oct 03Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Jun 23Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Mar 02Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Nov 11Recent updates
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely
Jul 13We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully
Feb 09Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Oct 03Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Jun 23Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Mar 02Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Nov 11AlloVir GAAP EPS of $0.69 beats by $1.42
Aug 04AlloVir stock surges on $126.6M securities offering
Jul 27Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?
Jul 27Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Mar 21AlloVir: A Comparative Study Of Its Manufacturing Process
Feb 07We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate
Nov 02AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues
Oct 02AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price
Aug 06We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Jul 01AlloVir EPS misses by $0.08
May 06AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans
Apr 01This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)
Feb 07Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?
Jan 08FDA clears AlloVir's ALVR106 application in respiratory viruses
Dec 17Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data
Dec 07We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Dec 04
AlloVir EPS misses by $0.28
Nov 10Financial Position Analysis
Short Term Liabilities: ALVR's short term assets ($129.9M) exceed its short term liabilities ($2.4M).
Long Term Liabilities: ALVR's short term assets ($129.9M) exceed its long term liabilities ($8.3M).
Debt to Equity History and Analysis
Debt Level: ALVR is debt free.
Reducing Debt: ALVR has no debt compared to 5 years ago when its debt to equity ratio was 8.2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALVR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALVR has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 28.8% each year.